[ACST] Acasti Pharma, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ACST
ACST is in the long-term down -98% below S&P in 13 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 10.71 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | ROE | ROI | ||||
| Current Ratio | Quick Ratio | Long Term Debt/Equity | Debt Ratio | ||||
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | Gross Profit | ||||
| Net Profit | Operating Profit | Total Assets | Total Current Assets | ||||
| Total Current Liabilities | Total Debt | Total Liabilities | Total Revenue |
Technical Data
| High 52 week | 3.1 | Low 52 week | 0.63 | Last close | 0.71 | Last change | 1.59% |
| RSI | 36.35 | Average true range | 0.04 | Beta | 0.3 | Volume | 4.94 M |
| Simple moving average 20 days | -2.49% | Simple moving average 50 days | -23.16% | Simple moving average 200 days | -39.8% |
Performance Data
| Performance Week | 7.92% | Performance Month | -34.26% | Performance Quart | -31.73% | Performance Half | -44.96% |
| Performance Year | -43.2% | Performance Year-to-date | -24.69% | Volatility daily | 6.55% | Volatility weekly | 14.65% |
| Volatility monthly | 30.03% | Volatility yearly | 104.04% | Relative Volume | 5202.7% | Average Volume | 196.58 K |
| New High | New Low |
News
2021-10-07 10:15:00 | Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of Acasti Pharma, Inc. In The Southern District Of New York
2021-10-06 08:30:00 | Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
2021-09-27 08:30:00 | Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
2021-09-22 08:30:00 | Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
2021-09-14 08:30:00 | Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21??
2021-09-08 08:30:00 | Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-31 14:27:54 | Why Shares of Acasti Pharma Slumped Tuesday
2021-08-27 08:40:00 | Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split
2021-08-25 07:02:41 | 21 Stocks Moving in Wednesday's Pre-Market Session
2021-08-12 07:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
2021-07-29 08:30:00 | Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
2021-07-23 08:30:00 | Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
2021-07-07 09:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates RAVN, SHSP, ICBK, ACST; Shareholders are Encouraged to Contact the Firm
2021-07-06 11:02:00 | SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Acasti Pharma Inc. Merger
2021-07-03 18:52:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates ACST, CLDR, DISCA, GRA, TRMT, XEC; Shareholders are Encouraged to Contact the Firm
2021-07-03 00:14:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST
2021-06-24 03:22:05 | Acasti Pharma Inc.'s CVE:ACST Shift From Loss To Profit
2021-06-22 07:00:00 | Acasti Pharma Provides Fiscal 2021 Year-End Business Update
2021-06-14 16:20:40 | 10 Best Biotech Penny Stocks to Buy Now
2021-05-17 07:00:00 | Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance
2021-05-13 18:05:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm
2021-05-12 17:31:00 | ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST
2021-05-07 11:53:48 | Acasti Pharma To Acquire Grace Therapeutics: Highlights
2021-05-07 07:00:00 | Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.
2021-03-08 17:30:00 | Acasti Pharma Provides Update on Recent Financing Activities
2021-02-09 06:55:00 | Acasti Pharma Announces Results for Third Quarter of Fiscal 2021
2021-01-27 06:55:00 | Acasti Pharma Provides Update on Recent Financing Activities
2020-12-25 12:00:05 | Acasti ACST Moves to Buy: Rationale Behind the Upgrade
2020-12-23 15:24:00 | Acasti Pharma Unaware of Any Material Change
2020-11-16 06:55:00 | Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
2020-11-12 05:43:52 | Here's Why Acasti Pharma CVE:ACST Must Use Its Cash Wisely
2020-09-29 06:55:00 | Acasti Announces Review Process of Strategic Alternatives
2020-09-16 06:55:00 | Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
2020-09-11 07:00:00 | Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
2020-09-01 14:10:28 | Acasti Pharma Stock Loses a Wall Street Supporter
2020-08-31 07:00:00 | Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
2020-08-14 12:00:04 | What Makes Acasti ACST a New Buy Stock
2020-08-13 08:30:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
2020-07-31 07:55:00 | Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
2020-07-06 14:37:43 | Why Acasti Pharma's Stock Is Trading Higher Today
2020-06-29 09:45:12 | Acasti Pharma Provides Fiscal 2020 Year-End Business Update
2020-06-19 08:00:10 | Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
2020-06-04 21:49:01 | Hedge Funds Souring On Acasti Pharma Inc. ACST
2020-05-06 06:25:05 | Does The Acasti Pharma Inc. CVE:ACST Share Price Fall With The Market?
2020-04-30 08:30:10 | Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
2020-04-20 08:30:10 | Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
2020-04-01 08:30:10 | Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
2020-03-11 08:00:10 | Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico